AI
Monday, December 23, 2019 9:56:30 AM
BXRX =MC $52 M --FDA Decision in Q1 for a BIG Drug -- unknown low float stock =500%++ UPSIDE .LIFETIME OPP
Janney starts Baudax Bio at buy; fair value estimate $12
https://biotuesdays.com/2019/11/22/janney-starts-baudax-bio-at-buy-fair-value-estimate-12/
Baudax’s key product is Anjeso, a long-acting intravenous formulation of meloxicam, an established non-opioid pain reliever, available through an oral formulation. “We see a high probability of FDA approval in the first quarter of 2020, which would be a meaningful catalyst to drive the stock towards our fair value,” writes analyst Ester Hong.
She estimates peak U.S. sales of $355-million for Anjeso but sees “upside from increased demand for a potent non-opioid that allows patients to recover and go home faster.”
Janney starts Baudax Bio at buy; fair value estimate $12
https://biotuesdays.com/2019/11/22/janney-starts-baudax-bio-at-buy-fair-value-estimate-12/
Baudax’s key product is Anjeso, a long-acting intravenous formulation of meloxicam, an established non-opioid pain reliever, available through an oral formulation. “We see a high probability of FDA approval in the first quarter of 2020, which would be a meaningful catalyst to drive the stock towards our fair value,” writes analyst Ester Hong.
She estimates peak U.S. sales of $355-million for Anjeso but sees “upside from increased demand for a potent non-opioid that allows patients to recover and go home faster.”
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
